CMV 2012 - combined 4th Congenital Cytomegalovirus Conference and 14th Internatio

描述(申请人提供)：人类巨细胞病毒(HCMV)是导致出生缺陷的主要病毒原因，其对医疗费用的影响是巨大的。大约1%的新生儿受到感染，在出生时有症状的13%中，50%将出现永久性损伤。至少有14%的无症状婴儿以后会出现残疾。在免疫功能低下的个体中，HCMV也是一个严重的问题，并与移植相关血管疾病的发展和血管成形术后的再狭窄有关。此外，已有研究表明，人巨细胞病毒可能在动脉粥样硬化的发生和多种肿瘤的发病机制中发挥作用。R13会议资助的首要目标是使初级研究人员(研究生/医学研究生和博士后研究员、初级教员)能够参加CMV 2012研讨会。旅行奖--使用这项申请产生的资金--将颁发给美国受训人员和初级教职员工的实验室，这是基于同行对提交的摘要的评分。CMV 2012是一次独特的会议，因为它将第4届先天性CMV大会和第14届国际CMV/BetaherpeVirus研讨会合并为一个统一的会议。CMV 2012的使命是将基础科学家、内科科学家、临床医生、来自行业和政府的代表以及受先天性CMV感染影响的家庭聚集在一个论坛上，在这个论坛上，可以广泛交流不同的想法，并广泛交流新概念，从而更好地了解、预防和/或治疗CMV疾病。以促进医学和人类健康为目标的翻译研究日益受到重视，这使得将这些不同的群体聚集在一起成为当务之急。CMV 2012研讨会将于2012年10月29日至11月2日在加利福尼亚州旧金山的观澜湾会议中心举行。先天性巨细胞病毒会议和国际巨细胞病毒/贝塔疱疹病毒研讨会的重点领域将在2012年巨细胞病毒大会上得到很好的代表。这次会议有四个同等的目标。目标1是通过国际公认的演讲者和该领域公认的领军人物以及工作处于前沿的年轻研究人员的组合，促进最高水平的科学卓越。目的2强调与重要临床问题高度相关并有可能转化为医学实践的研究。目标3是促进产业界、基础和临床科学家以及政府机构之间的新的合作和伙伴关系。目标4促进公众教育和认识先天性巨细胞病毒感染的流行及其对社会的影响。 公共卫生相关性：人类巨细胞病毒(CMV)是与感染性病原体有关的出生缺陷的主要原因。此外，它也是免疫抑制患者，包括器官和造血移植受者以及艾滋病患者的发病率和死亡率的主要原因。学术界、临床和产业界正在致力于改进治疗方法和开发针对这些病毒的有效疫苗。CMV 2012将是专门讨论这一重要人类病原体的临床、病毒学、分子、免疫学和社会学方面的广泛主题的卓越场所。

Description (as provided by the applicant): Human cytomegalovirus (HCMV) is the major viral cause of birth defects, and its impact on health care costs is enormous. Approximately 1% of newborns are infected, and of the 13% that are symptomatic at birth, 50% will have permanent impairment. At least 14% of asymptomatic infants will later show disabilities. HCMV is also a serious problem in immunocompromised individuals and has been associated with the development of transplant-associated vascular disease and restenosis following angioplasty. Additionally, it has been proposed that HCMV may play a role in the development of atherosclerosis and the pathogenesis of several types of tumors. The overarching goal of this R13 conference grant is to enable junior investigators (graduate/medical students and postdoctoral fellows, junior faculty) to attend the CMV 2012 Workshop. Travel awards - using funds generated by this application - will be awarded to laboratories of U.S.-based trainees and junior faculty based on peer reviewed scoring of submitted abstracts. CMV 2012 is a unique meeting in that it combines the 4th Congenital CMV Conference and the 14th International CMV/Betaherpesvirus Workshop into a unified conference. The mission of CMV 2012 is to bring together basic scientists, physician scientists, clinicians, representatives from industry and government, and families affected by congenital CMV infection in a forum where there can be a broad exchange of diverse ideas and extensive cross-fertilization of new concepts that lead to a better understanding, prevention, and/or treatment of CMV disease. The increasing emphasis on translational research with the goal of advancing medicine and human health has made it imperative to bring these different groups together. The CMV 2012 Workshop will be held October 29th to November 2nd, 2012 at the Mission Bay Conference Center in San Francisco, California. The areas of focus of both the Congenital CMV Conferences and the International CMV/Betaherpesvirus Workshop will be well-represented at CMV 2012. There are four coequal aims of this meeting. Aim 1 is to facilitate the highest level of scientific excellence with a combination of speakers who are internationally recognized and established leaders in the field, as well as younger investigators whose work is at the cutting edge. Aim 2 emphasizes the research that is highly relevant to important clinical questions and has potential for translation into medical practice. Aim 3 is to foster new collaborations and partnerships between industry, basic and clinical scientists, and government agencies. Aim 4 promotes public education and awareness of the prevalence of congenital CMV infection and impact on society. Public Health Relevance: Human cytomegalovirus (CMV) is the leading cause of birth defects associated with an infectious agent. Moreover, it is a major cause of morbidity and mortality in immunosuppressed patients, including organ and hematopoietic transplant recipients, and AIDS patients. Significant effort in academia, the clinic and industry is being devoted to improve therapies and develop effective vaccines against these viruses. CMV 2012 will be the preeminent venue devoted solely to the broad range of topics encompassing the clinical, virological, molecular, immunological, and societal aspects of this important human pathogen.